C7118
Cefdinir
≥97.0% (HPLC)
别名:
syn-7-[2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid, BMY-28488, FK-482, [6R-[6α-7beta(Z)]]-7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChI
1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1
InChI key
RTXOFQZKPXMALH-GHXIOONMSA-N
assay
≥97.0% (HPLC)
form
powder or crystals
pKa
9.70
mp
170 °C
antibiotic activity spectrum
Gram-negative bacteria, Gram-positive bacteria
mode of action
cell wall synthesis | interferes
storage temp.
room temp
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
Chemical structure: β-lactam
Application
An advanced-generation, cephalosporin antibiotic. Used for its excellent and well balanced antibacterial activities against gram-positive and gram-negative bacteria.
Cefdinir was used to study bacterial infections caused by Staphylococcus aureus and Neisseria gonorrhoeae and the horizontal transfer of the ftsI gene in H. influenzae.
Biochem/physiol Actions
Cefdinir is an advanced generation amino-2-thiazolyl cephalosporin effective against Gram-positive and Gram-negative bacteria. It acts by disrupting the synthesis of the peptidoglycan layer of bacterial cell walls. It is also known to inhibit human neutrophil myeloperoxidases.
Other Notes
Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
H Akiyama et al.
The Journal of antimicrobial chemotherapy, 48(4), 487-491 (2001-10-03)
We examined the antibacterial action of several tannins on plasma coagulation by Staphylococcus aureus and the effect of conventional chemotherapy combined with tannic acid below the MIC. Coagulation was inhibited in plasma containing tannic acid (100 mg/L), gallic acid (5000
Visual diagnosis: four infants who have red, "bloody" stools.
Jill Lowers et al.
Pediatrics in review, 30(4), 146-149 (2009-04-03)
Junsung Park et al.
International journal of pharmaceutics, 396(1-2), 239-245 (2010-07-06)
The aim of this study was to investigate the effects of micronization and amorphorization of cefdinir on solubility and dissolution rate. The amorphous samples were prepared by spray-drying (SD) and supercritical anti-solvent (SAS) process, respectively and their amorphous natures were
D R Guay
The Pediatric infectious disease journal, 19(12 Suppl), S141-S146 (2001-01-06)
Oral second and third generation cephalosporins are undergoing continuing research and development in the arena of pediatric infectious disease in an attempt to fill voids created by existing agents in the quest for the "ideal" antimicrobial. This paper reviews the
M T Labro et al.
Journal of immunology (Baltimore, Md. : 1950), 152(5), 2447-2455 (1994-03-01)
Cefdinir, a new oral 2-amino-5-thiazolyl cephalosporin, inhibited the luminol-amplified chemiluminescence (LACL) response of human neutrophils stimulated by PMA but not opsonized zymosan, in a concentration-dependent but not time-dependent manner. The LACL response to opsonized zymosan in cytochalasin B-treated neutrophils was
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持